Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
D020909:Acarbose; D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005951:Glucose Tolerance Test; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008320:Maltose / Q000008:administration & dosage; D009844:Oligosaccharides / Q000627:therapeutic use*; D013395:Sucrose / Q000008:administration & dosage; D014312:Trisaccharides / Q000627:therapeutic use*
D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D009844:Oligosaccharides; D014312:Trisaccharides; D013395:Sucrose; D008320:Maltose; D005959:Glucosidases; D020909:Acarbose